There are currently two rIL-22-based therapies, including F-652 (IL-22 fused with constant region of IgG2) and UTTR1147A (IL-22 fused with IgG4), in clinical trials exploring their tissue protective functions in several inflammatory diseases (alcoholic hepatitis (AH), inflammatory bowel disease (IBD), acute graft-versus-host disease (GvHD) and neuropathic diabetic foot ulcers) [79]. This evidence concerns the gene IL22 and alcoholic hepatitis.